Since the US Food and Drug Administration’s acceptance of Madrigal Pharmaceutical’s (Nasdaq: MDGL) new drug application (NDA) and priority review for its THR-β agonist (resmetirom) in non-alcoholic steatohepatitis (NASH) in September 2023, the company has taken steps to fortify its leadership and financial position to gear up for the imminent launch of resmetirom.
The measures initiated by Madrigal for the launch are expected to set the tone for future launches of NASH therapies by other small companies, according to data and analytics company GlobalData.
In a pivotal move aligning with its vision for resmetirom, Madrigal made strategic changes in its leadership with the addition of two seasoned Sanofi alumni; Bill Sibold as chief executive officer (CEO) and Carole Huntsman as chief commercial officer (CCO).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze